BRIDGEWATER, N.J., Feb. 26 /PRNewswire-FirstCall/ -- Sanofi-aventis announced today that the U.S. Food and Drug Administration (FDA) approved Apidra(R) SoloSTAR(R ...

PARIS, June 25 Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that results from the RAndomized Study of Basal Bolus Insulin Therapy in the Inpatient Management of Patients with Type 2 ...

The approval of Apidra (R) for pediatric use is based upon FDA review of a 26-week, phase III, open-label, active control study of Apidra (R) in comparison with insulin lispro, in 572 children and ...

The FDA has approved Apidra (insulin glulisine [rDNA origin] injection, from sanofi-aventis) for the treatment of type 1 diabetes in children ≥4 years old. This approval was based on a 26-week, ...

The FDA has approved Apidra SoloSTAR (insulin glulisine[rDNA origin] injection, from sanofi-aventis), a prefilled disposable pencontaining Apidra. Apidra SoloSTAR makes administration of insulin ...

European Commission approves Apidra for diabetes Apidra has a rapid onset and short duration of action which allows covering the postprandial hyperglycaemic peaks. It should normally be used in ...

Oct. 5, 2004 — The European Commission has approved for use in the European Union an expanded dosing indication for darbepoetin alfa, etanercept for moderate to severe plaque psoriasis, insulin ...

To earn CME related to this news article, click here. January 6, 2009 — The US Food and Drug Administration (FDA) has approved revisions to the safety labeling, adding adverse event information for ...

BRIDGEWATER, N.J. The Food and Drug Administration has approved Apidra, a drug for improving glycemic control in diabetic children aged 4 and older, manufacturer Sanofi-Aventis said Wednesday. The FDA ...

Adocia, a biotechnology company specialized in the development of ‘best-in-class’ medicines from already approved therapeutic proteins, in particular proteins and oncologic treatments, launches today ...

Sanofi-aventis announces results from a new study show that adding Apidra to a Basal insulin and Oral antidiabetic drug Therapy (BOT+ or Basal plus) may provide an effective treatment option for ...